| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Myriad Genetics Inc (NASDAQ: MYGN)
MYGN Technical Analysis
2
| As on 9th Jun 2023 MYGN STOCK Price closed @ 23.30 and we RECOMMEND Buy for LONG-TERM with Stoploss of 22.69 & Strong Sell for SHORT-TERM with Stoploss of 25.84 we also expect STOCK to react on Following IMPORTANT LEVELS. |
MYGNSTOCK Price
| Open | 23.27 | Change | Price | % |
| High | 23.47 | 1 Day | 0.04 | 0.17 |
| Low | 23.01 | 1 Week | 1.01 | 4.53 |
| Close | 23.30 | 1 Month | 1.93 | 9.03 |
| Volume | 256100 | 1 Year | -1.57 | -6.31 |
| 52 Week High 28.01 | 52 Week Low 14.51 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| MYGN Daily Charts |
MYGN Intraday Charts |
Whats New @ Bazaartrend |
MYGN Free Analysis |
|
|
MYGN Important Levels Intraday
| RESISTANCE | 24.19 |
| RESISTANCE | 23.90 |
| RESISTANCE | 23.73 |
| RESISTANCE | 23.55 |
| SUPPORT | 23.05 |
| SUPPORT | 22.87 |
| SUPPORT | 22.70 |
| SUPPORT | 22.41 |
MYGN Forecast May 2024
| 4th UP Forecast | 31.82 |
| 3rd UP Forecast | 29.09 |
| 2nd UP Forecast | 27.4 |
| 1st UP Forecast | 25.71 |
| 1st DOWN Forecast | 20.89 |
| 2nd DOWN Forecast | 19.2 |
| 3rd DOWN Forecast | 17.51 |
| 4th DOWN Forecast | 14.78 |
MYGN Weekly Forecast
| 4th UP Forecast | 28.29 |
| 3rd UP Forecast | 26.69 |
| 2nd UP Forecast | 25.70 |
| 1st UP Forecast | 24.71 |
| 1st DOWN Forecast | 21.89 |
| 2nd DOWN Forecast | 20.90 |
| 3rd DOWN Forecast | 19.91 |
| 4th DOWN Forecast | 18.31 |
MYGN Forecast2024
| 4th UP Forecast | 51.3 |
| 3rd UP Forecast | 42.32 |
| 2nd UP Forecast | 36.77 |
| 1st UP Forecast | 31.22 |
| 1st DOWN Forecast | 15.38 |
| 2nd DOWN Forecast | 9.83 |
| 3rd DOWN Forecast | 4.28 |
| 4th DOWN Forecast | -4.7 |
Myriad Genetics Inc ( NASDAQ USA Symbol : MYGN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
MYGN Business Profile
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah. Address: 320 Wakara Way, Salt Lake City, UT, United States, 84108
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service